In The Claims

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-23 (canceled)

24. (Previously Presented) A method for the prevention or treatment of tumors, in particular malignant tumors, wherein eukaryotic cells are treated with an active ingredient which influences, in particular inhibits, the expression or the function of proteins synthesized or secreted by tumors, and thus at least partially inhibits the increase in tissue volume or the metastasis of the tumors.

25. (Currently Ameneded) A method for diagnosing disorders associated with tumors in particular malignant tumors, wherein eukaryotic cells are brought into contact with a substance which ~~with~~ detects the expression or the function of proteins synthesized or secreted by tumors.

26. (Previously Presented) The method as claimed in claim 24, wherein the proteins synthesized or secreted by tumors are the proteins of table 1, in particular the isoforms thereof.

27. (Previously Presented) The method as claimed in claim 24, wherein the active ingredient or the substance is directed against the proteins synthesized or secreted by tumors.

28. (Previously Presented) The method as claimed in claim 24, wherein the active ingredient or the substance is directed against activators, inhibitors, regulators or biological precursors of proteins synthesized or secreted by tumors.

29. (Previously Presented) The method as claimed in claim 24, wherein the active ingredient or the substance is a polynucleotide which encodes a peptide, in particular a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression or function of proteins synthesized or secreted by tumors.

30. (Previously Presented) The method as claimed in claim 24, wherein the active ingredient or the substance is a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression or function of proteins synthesized or secreted by tumors.

31. (Previously Presented) The method as claimed in claim 24, wherein the active ingredient or the substance is a small molecular compound, preferably a

small molecular compound having a molecular weight (MW) of < 1000.

32. (Previously Presented) The method as claimed in claim 24, wherein the malignant tumors are prostatic carcinomas.

33. (Previously Presented) The method as claimed in claim 24, wherein the active ingredient or the substance can be administered orally, intravenously, topically or by inhalation.

34. (Previously Presented) A pharmaceutical composition comprising an effective amount of at least one active ingredient with influences, in particular inhibits, the expression or function of proteins synthesized or secreted by tumors, in particular malignant tumors, and, where appropriate, a pharmaceutical carrier.

35. (Previously Presented) The pharmaceutical composition of claim 34, wherein the active ingredient is a polynucleotide which encodes a peptide, in particular a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression or function of proteins synthesized or secreted by tumors, in particular malignant tumors.

36. (Previously Presented) The pharmaceutical composition of claim 34, wherein the active ingredient is a peptide, preferably a polypeptide, this peptide

preferably influencing, in particular inhibiting, the expression or function of proteins synthesized or secreted by tumors, in particular malignant tumors.

37. (Previously Presented) The pharmaceutical composition of claim 34, wherein the active ingredient is a small molecular compound, preferably a small molecular compound having a molecular weight (MW) of < 1000.

38. (Previously Presented) A pharmaceutical composition comprising an effective amount of at least one active ingredient which influences, in particular inhibits, the expression or function of activators, inhibitors, regulators or biological precursors of proteins synthesized or secreted by tumors, in particular malignant tumors, and, where appropriated, a pharmaceutical carrier.

39. (Previously Presented) The pharmaceutical composition of claim 38, wherein the active ingredient is a polynucleotide which encodes a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression or function of activators, inhibitors, regulators or biological precursors of proteins synthesized or secreted by tumors, in particular malignant tumors.

40. (Previously Presented) The pharmaceutical composition of claim 38, wherein the active ingredient is a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression or function of activators, inhibitors, regulators or biological precursors of proteins synthesized or secreted by tumors, in particular malignant tumors.

41. (Previously Presented) The pharmaceutical composition of claim 38, wherein the active ingredient is a small molecular compound, preferably a small molecular compound having a molecular weight (MW) of < 1000.

42. (Previously Presented) A diagnostic kit comprising at least one substance for detecting the expression or function of proteins synthesized or secreted by tumors, in particular malignant tumors, for diagnosing disorders associated with these tumors.

43. (Previously Presented) The diagnostic kit of claim 42 for diagnosing prostatic carcinomas.

44. (Previously Presented) The method as claimed in claim 25, wherein the proteins synthesized or secreted by tumors are the proteins of table 1, in particular the isoforms thereof.

45. (Previously Presented) The method as claimed in claim 25, wherein the active ingredient or the substance is directed against the proteins synthesized or secreted by tumors.

46. (Previously Presented) The method as claimed in claim 25, wherein the active ingredient or the substance is directed against activators, inhibitors, regulators or biological precursors of proteins synthesized or secreted by tumors.

47. (Previously Presented) The method as claimed in claim 25, wherein the active ingredient or the substance is a polynucleotide which encodes a peptide, in particular a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression or function of proteins synthesized or secreted by tumors.

48. (Previously Presented) The method as claimed in claim 25, wherein the active ingredient or the substance is a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression or function of proteins synthesized or secreted by tumors.

49. (Previously Presented) The method as claimed in claim 25, wherein the active ingredient or the substance is a small molecular compound, preferably a small molecular compound having a molecular weight (MW) of < 1000.

50. (Previously Presented) The method as claimed in claim 25, wherein the malignant tumors are prostatic carcinomas.

51. (Previously Presented) The method as claimed in claim 25, wherein the active ingredient or the substance can be administered orally, intravenously, topically or by inhalation.